|
MechanismCD40L stimulants |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 1 A Phase 1b Study to Assess the Safety, Tolerability and Pharmacokinetics of OPT101 in Patients with Community Acquired Pneumonia (CAP) with Sepsis
OPT101-100-40 is a multicenter, randomized, placebo-controlled, multiple-ascending-dose, sequential-group, investigator- and participant-blinded, sponsor-unblinded, study of OPT101 vs placebo when administered for up to 4 days to patients admitted to the hospital for treatment of Community Acquired Pneumonia (CAP) with sepsis.
This study will be performed in patients with Community Acquired Pneumonia (CAP) with Sepsis, who are 18 years or older to evaluate the safety and tolerability of OPT101 in a population with elevated levels of pathologic CD40.
A Phase 1b Study of OPT101 in Patients With Type 1 Diabetes
Phase 1b designed to assess safety, pharmacokinetics, immunological and clinical effects of multiple ascending doses of OPT101.
100 Clinical Results associated with OP LLC
0 Patents (Medical) associated with OP LLC
100 Deals associated with OP LLC
100 Translational Medicine associated with OP LLC